Yoshinori Ito
Experienced in Myoclonic Epilepsy Associated With Ragged Red Fibers

Yoshinori Ito

Tokyo, JP 
Experienced in Myoclonic Epilepsy Associated With Ragged Red Fibers
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Yoshinori Ito practices in Tokyo, Japan. Mr. Ito is rated as an Experienced expert by MediFind in the treatment of Myoclonic Epilepsy Associated With Ragged Red Fibers. His top areas of expertise are Esophageal Cancer, Breast Cancer, Mononucleosis, Mastectomy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 566 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Myoclonic Epilepsy Associated With Ragged Red Fibers.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Takaidonishi, 1688535, Japan
Kahoku, 9200293, Japan
Nagakute, Japan
Hatanodai, 1428666, Japan
Ichinomiya, Japan
Nagoya, 4648547, Japan
3191195, Japan
Itabashi, 1738610, Japan
Okazaki, Japan
Ariake, 1358550, Japan
Takatsuki, Japan
Kurokami, 8608555, Japan
Chuo, 1040045, Japan
Tokai, 3191195, Japan
Yokohama, 2270043, Japan
Karatsu, 8478588, Japan
Tsukiji, 1040045, Japan
Wako, 3510198, Japan
Toyohashi, 4418580, Japan
Kobe, 6500011, Japan
Gifu-shi, Japan
Sayo, 6795148, Japan
Kurashiki, Japan
Shinjuku, 1631328, Japan
Saitama, Japan
Osaka, Japan
Chuo, Japan
Hibarigaoka, 4418580, Japan
Sendai, 9808578, Japan
Shibuya, 1508935, Japan
Kashiwa, 2778581, Japan
Oita, Japan
Matsumoto, Japan
Shiba, Japan
Toshima, 1708455, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

565 Total Publications

Anal Canal Squamous Cell Carcinoma Following Low-Dose-Rate Prostate Brachytherapy: A Report of Two Cases and Literature Review.
Anal Canal Squamous Cell Carcinoma Following Low-Dose-Rate Prostate Brachytherapy: A Report of Two Cases and Literature Review.
Journal: Cureus
Published: September 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ito's expertise for a condition
ConditionClose
View All 15 Advanced Conditions
View All 119 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile